Bernstein Harold Sells 16,142 Maze Therapeutics Shares

On August 15, 2026, Harold Bernstein, R&D president and Chief Medical Officer (CMO) of Maze Therapeutics, Inc. (MAZE), sold 16,142 shares of the company at a per-unit price of $27.61, totaling $445,620.

Who is Harold Bernstein and What is His Real Role at Maze Therapeutics

Harold Bernstein holds the position of R&D president and CMO at Maze Therapeutics. In this role, he is responsible for directing and overseeing the company's research and development activities, as well as its medical strategy. His responsibilities include making informed decisions regarding research projects, clinical trials, and the development of new products. As a member of senior management, Harold has access to privileged information about ongoing projects and the company's future prospects, enabling him to make informed investment decisions.

As R&D president and CMO, Harold plays a crucial role in shaping and implementing the company's development strategy. He collaborates closely with other members of senior management to identify growth opportunities and develop plans to achieve the company's objectives. His expertise in the fields of research and development allows him to provide strategic advice and make informed decisions that directly impact the company's success.

Transaction Details: 16,142 shares at $27.61 each

The transaction executed by Harold Bernstein involved the sale of 16,142 Maze Therapeutics shares at a per-unit price of $27.61. It is important to note that this transaction was completed on August 15, 2026, and was filed with the SEC within two business days afterward, in compliance with SEC Form 4 rules. The total value of the transaction amounts to $445,620, representing the proceeds from the sale of the 16,142 shares.

Why Insiders Sell Their Shares – Possible Reasons

There are several reasons why insiders, such as Harold Bernstein, might choose to sell their shares. One possible reason is portfolio diversification. Insiders may decide to sell a portion of their shares to spread their investments and reduce their exposure to a single stock. Another reason could be tax planning, as selling shares can generate income that may be used to satisfy tax obligations.

Another possible reason for insiders selling their shares is the need for liquidity. Insiders may require cash for personal reasons, such as purchasing real estate or funding personal projects. It is also possible that the sale of shares could be motivated by a bearish outlook on the company or its sector, though this cannot be confirmed without further information. It is essential to consider that insiders may sell their shares for personal reasons and not necessarily due to a negative outlook on the company.

How Individual Investors Track Form 4 Filings

Individual investors can monitor the Form 4 filings submitted by insiders by visiting the SEC's EDGAR (Electronic Data Gathering, Analysis, and Retrieval) website. This site provides free access to Form 4 filings, which contain detailed information about transactions executed by insiders. Investors can also use online tools and services to track Form 4 filings and receive alerts when an insider completes a transaction.

However, it is important to note that while tracking insider sales can provide valuable insights, it should be done with caution. Insider selling does not always indicate negative sentiment about the company, as insiders may sell shares for a variety of legitimate reasons, including diversification or tax planning. Investors should consider this context when interpreting insider transactions and should not make investment decisions based solely on such information.